<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <title>Healthcare Stocks | Statmint</title>
  <link rel="icon" href="statmint_logo.jpeg" type="image/jpeg" />
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet"/>
  <link href="https://unpkg.com/aos@2.3.4/dist/aos.css" rel="stylesheet"/>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600&display=swap" rel="stylesheet"/>
  <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
  <style>
    body {
      font-family: 'Inter', sans-serif;
      background: #f9fafb;
      color: #212529;
      margin: 0;
    }

    header {
      background: #0a0a0a;
      padding: 1rem 2rem;
      display: flex;
      justify-content: space-between;
      align-items: center;
    }

    header img {
      height: 180px;
    }

    nav a {
      margin-left: 1rem;
      color: white;
      text-decoration: none;
      font-weight: 500;
    }

    nav a:hover {
      color: #1a73e8;
    }

    .hero {
      background: linear-gradient(rgba(0,0,0,0.6), rgba(0,0,0,0.6)),
                  url('topstats-cover.jpg') center/cover no-repeat;
      color: white;
      text-align: center;
      padding: 6rem 2rem;
    }

    .hero h1 {
      font-size: 2.8rem;
      font-weight: 600;
    }

    .hero p {
      max-width: 720px;
      margin: 1rem auto 0;
      font-size: 1.15rem;
      color: #ddd;
    }

    .stock-card {
      background: white;
      border: 1px solid #dee2e6;
      border-radius: 12px;
      padding: 2rem;
      box-shadow: 0 4px 12px rgba(0,0,0,0.03);
      height: 100%;
      display: flex;
      flex-direction: column;
      justify-content: space-between;
    }

    .stock-card h5 {
      font-size: 1.2rem;
      font-weight: 600;
    }

    .stock-card p {
      font-size: 0.95rem;
      line-height: 1.5;
    }

    .price-list {
      padding-left: 0;
      font-size: 0.85rem;
    }

    .price-list li {
      list-style: none;
      border-bottom: 1px solid #eee;
      padding: 0.25rem 0;
    }

    .card-footer {
      display: flex;
      gap: 0.5rem;
      margin-top: 1rem;
      flex-wrap: wrap;
    }

    .btn-sm {
      font-size: 0.8rem;
      padding: 0.4rem 0.75rem;
    }

    footer {
      background: #0a0a0a;
      color: #bbb;
      text-align: center;
      padding: 2rem 1rem;
    }

    footer a {
      color: #1a73e8;
    }

    @media (max-width: 768px) {
      .stock-card {
        padding: 1.25rem;
      }

      .stock-card h5 {
        font-size: 1.05rem;
      }

      canvas {
        width: 100% !important;
        height: auto !important;
      }

      .card-footer {
        flex-direction: column;
      }
    }
  </style>
</head>
<body>

<header>
  <a href="index.html"><img src="statmint_logo.jpeg" alt="Statmint Logo"></a>
  <nav>
    <a href="index.html">Home</a>
    <a href="stocks.html">Healthcare Stocks</a>
    <a href="fda.html">FDA Approvals</a>
    <a href="ipos.html">Initial Public Offerings</a>
  </nav>
</header>

<section class="hero" data-aos="fade-zoom-in">
  <h1>Healthcare Stocks</h1>
  <p>Track companies with active clinical pipelines, FDA review status, and recent IPOs.</p>
</section>

<section class="container-fluid py-5" id="stock-sections"></section>

<footer>
  <div class="container">
    <p>Â© 2025 Statmint. Data is for research purposes only and does not constitute financial advice.</p>
  </div>
</footer>

<script src="https://unpkg.com/aos@2.3.4/dist/aos.js"></script>
<script>
  AOS.init({ duration: 1000, once: true, easing: 'ease-in-out' });

  const labels = ["Jul 2023","Aug","Sep","Oct","Nov","Dec","Jan 2024","Feb","Mar","Apr","May","Jun"];

  const pipeline = [
  {
    name: "Moderna",
    summary: "mRNA vaccines and therapeutics for infectious diseases and rare conditions.",
    ticker: "MRNA",
    candidate: "mRNA-1345",
    indication: "RSV Vaccine (Older Adults)",
    phase: "Phase III",
    trialStatus: "Primary endpoint met; BLA filing expected late 2024.",
    competitors: ["Pfizer", "GSK"],
    ipoDate: "Dec 2018",
    prices: [140, 145, 142, 148, 150, 153, 155, 160, 162, 158, 155, 150],
    website: "https://www.modernatx.com"
  },
  {
    name: "BioNTech",
    summary: "mRNA immunotherapies for oncology and infectious diseases.",
    ticker: "BNTX",
    candidate: "BNT162b2 Combo",
    indication: "COVID-19 + Influenza Combo Vaccine",
    phase: "Phase II/III",
    trialStatus: "Enrolling; interim data mid-2024.",
    competitors: ["Moderna", "CureVac"],
    ipoDate: "Oct 2019",
    prices: [100, 98, 95, 97, 99, 102, 105, 104, 107, 110, 108, 105],
    website: "https://biontech.com"
  },
  {
    name: "Vertex Pharmaceuticals",
    summary: "Leader in cystic fibrosis and novel pain therapeutics.",
    ticker: "VRTX",
    candidate: "VX-548",
    indication: "Non-opioid Pain Treatment",
    phase: "Phase III",
    trialStatus: "Pivotal trials enrolling; NDA expected 2025.",
    competitors: ["Pfizer", "Eli Lilly"],
    ipoDate: "Jul 1991",
    prices: [300, 310, 320, 315, 318, 325, 330, 340, 335, 345, 340, 335],
    website: "https://www.vrtx.com"
  },
  {
    name: "Alnylam Pharmaceuticals",
    summary: "RNA interference therapies for rare genetic diseases.",
    ticker: "ALNY",
    candidate: "Vutrisiran",
    indication: "ATTR Amyloidosis",
    phase: "Phase III",
    trialStatus: "Phase III readout expected Q3 2024.",
    competitors: ["Ionis Pharmaceuticals"],
    ipoDate: "Jun 2004",
    prices: [190, 195, 192, 198, 200, 205, 202, 207, 210, 208, 205, 200],
    website: "https://www.alnylam.com"
  },
  {
    name: "CRISPR Therapeutics",
    summary: "CRISPR-based gene editing for blood disorders and cancer.",
    ticker: "CRSP",
    candidate: "CTX001",
    indication: "Beta Thalassemia & Sickle Cell",
    phase: "Regulatory Review",
    trialStatus: "BLA submitted; FDA review ongoing 2024.",
    competitors: ["Bluebird Bio"],
    ipoDate: "Oct 2016",
    prices: [50, 52, 55, 57, 59, 60, 63, 65, 62, 60, 58, 57],
    website: "https://www.crisprtx.com"
  },
  {
    name: "Regeneron Pharmaceuticals",
    summary: "Antibody therapies for serious diseases and oncology.",
    ticker: "REGN",
    candidate: "Odronextamab",
    indication: "Relapsed/Refractory Lymphoma",
    phase: "Phase II/III",
    trialStatus: "Pivotal study enrolling, data expected late 2024.",
    competitors: ["Roche", "AbbVie"],
    ipoDate: "Apr 1991",
    prices: [800, 820, 810, 830, 835, 840, 850, 845, 855, 860, 855, 850],
    website: "https://www.regeneron.com"
  },
  {
    name: "Beam Therapeutics",
    summary: "Base-editing therapies for genetic blood disorders.",
    ticker: "BEAM",
    candidate: "BEAM-101",
    indication: "Sickle Cell Disease",
    phase: "Phase I/II",
    trialStatus: "First patients dosed; early readout expected Q1 2025.",
    competitors: ["CRISPR Therapeutics", "Bluebird Bio"],
    ipoDate: "Feb 2020",
    prices: [40, 42, 43, 44, 46, 47, 48, 49, 50, 52, 51, 50],
    website: "https://www.beamtx.com"
  },
  {
    name: "Intellia Therapeutics",
    summary: "In vivo and ex vivo CRISPR gene-editing for rare diseases.",
    ticker: "NTLA",
    candidate: "NTLA-2002",
    indication: "Hereditary Angioedema",
    phase: "Phase I/II",
    trialStatus: "Dose escalation ongoing; interim data late 2024.",
    competitors: ["Ionis", "Takeda"],
    ipoDate: "May 2016",
    prices: [35, 37, 38, 36, 39, 40, 42, 41, 43, 45, 44, 42],
    website: "https://www.intelliatx.com"
  },
  {
    name: "Sarepta Therapeutics",
    summary: "Precision medicine for neuromuscular disorders.",
    ticker: "SRPT",
    candidate: "SRP-9001",
    indication: "Duchenne Muscular Dystrophy",
    phase: "Regulatory Review",
    trialStatus: "BLA submitted; FDA decision expected 2024.",
    competitors: ["Pfizer", "Solid Biosciences"],
    ipoDate: "Jun 1997",
    prices: [120, 123, 125, 127, 130, 128, 126, 129, 131, 130, 128, 126],
    website: "https://www.sarepta.com"
  },
  {
    name: "Immunocore Holdings",
    summary: "TCR therapeutics for cancer and viral infections.",
    ticker: "IMCR",
    candidate: "IMC-F106C",
    indication: "Cutaneous Melanoma",
    phase: "Phase I/II",
    trialStatus: "Phase II expansion ongoing; data update Q4 2024.",
    competitors: ["Bristol Myers Squibb", "Merck"],
    ipoDate: "Feb 2021",
    prices: [55, 58, 57, 60, 62, 63, 64, 66, 65, 67, 66, 65],
    website: "https://www.immunocore.com"
  },
  {
    name: "Relay Therapeutics",
    summary: "Small molecule precision therapies for cancer and rare diseases.",
    ticker: "RLAY",
    candidate: "RLY-4008",
    indication: "Cholangiocarcinoma",
    phase: "Phase II",
    trialStatus: "Phase II expansion study underway.",
    competitors: ["Blueprint Medicines"],
    ipoDate: "Jul 2020",
    prices: [12, 14, 13, 15, 16, 17, 18, 17, 16, 15, 16, 17],
    website: "https://www.relaytx.com"
  },
  {
    name: "Verve Therapeutics",
    summary: "Gene editing to permanently lower LDL cholesterol.",
    ticker: "VERV",
    candidate: "VERVE-101",
    indication: "Familial Hypercholesterolemia",
    phase: "Phase I",
    trialStatus: "Dose escalation ongoing; initial data mid-2024.",
    competitors: ["Alnylam", "Ionis"],
    ipoDate: "Jun 2021",
    prices: [20, 22, 21, 23, 24, 25, 26, 27, 26, 25, 24, 23],
    website: "https://www.vervetx.com"
  },
  {
    name: "Editas Medicine",
    summary: "CRISPR gene editing for inherited eye disorders and rare diseases.",
    ticker: "EDIT",
    candidate: "EDIT-101",
    indication: "Leber Congenital Amaurosis",
    phase: "Phase I/II",
    trialStatus: "Dose escalation ongoing; Phase II data mid-2024.",
    competitors: ["CRISPR Therapeutics"],
    ipoDate: "Feb 2016",
    prices: [8, 9, 8.5, 9.5, 10, 10.5, 11, 11.5, 11, 10.5, 10, 9.5],
    website: "https://www.editasmedicine.com"
  },
  {
    name: "Sana Biotechnology",
    summary: "Cell-based therapies for genetic diseases and tissue regeneration.",
    ticker: "SANA",
    candidate: "SG295",
    indication: "Liver Regeneration",
    phase: "Phase I",
    trialStatus: "First patients treated; safety data expected 2024.",
    competitors: ["Beam Therapeutics"],
    ipoDate: "Feb 2021",
    prices: [5, 5.5, 5.8, 6, 6.5, 6.8, 7, 7.2, 7, 6.8, 6.5, 6.2],
    website: "https://www.sanabiotech.com"
  },
    [
  {
    name: "Recursion Pharmaceuticals",
    summary: "AI-driven drug discovery across oncology, rare diseases, and inflammation.",
    ticker: "RXRX",
    candidate: "REC-994",
    indication: "Cerebral Cavernous Malformation",
    phase: "Phase II",
    trialStatus: "Phase II data expected Q4 2025.",
    competitors: ["SchrÃ¶dinger", "Insitro"],
    ipoDate: "Apr 2021",
    prices: [10.2, 10.8, 11.5, 11.9, 12.3, 12.5, 13, 12.8, 13.1, 13.4, 13, 12.7],
    website: "https://www.recursion.com"
  },
  {
    name: "Roivant Sciences",
    summary: "Platform biotech focused on inflammation and autoimmune diseases.",
    ticker: "ROIV",
    candidate: "IMVT-1402",
    indication: "Thyroid Eye Disease",
    phase: "Phase I/II",
    trialStatus: "Initial dosing complete; expansion in 2025.",
    competitors: ["Horizon Therapeutics", "Amgen"],
    ipoDate: "Oct 2021",
    prices: [7.5, 7.8, 8, 8.2, 8.4, 8.7, 9, 9.2, 9.5, 9.7, 9.6, 9.3],
    website: "https://www.roivant.com"
  },
  {
    name: "Apellis Pharmaceuticals",
    summary: "Leader in complement immunotherapy for rare and eye diseases.",
    ticker: "APLS",
    candidate: "Pegcetacoplan",
    indication: "Geographic Atrophy (Eye Disease)",
    phase: "Approved in EU, Phase III in US",
    trialStatus: "Real-world data analysis ongoing.",
    competitors: ["Iveric Bio", "Regeneron"],
    ipoDate: "Nov 2017",
    prices: [45, 47, 48, 49, 50, 52, 53, 52, 51, 50, 49, 48],
    website: "https://apellis.com"
  },
  {
    name: "Omega Therapeutics",
    summary: "Epigenomic controllers to regulate gene expression in oncology.",
    ticker: "OMGA",
    candidate: "OTX-2002",
    indication: "Hepatocellular Carcinoma",
    phase: "Phase I/II",
    trialStatus: "Dose escalation enrolling Q2 2025.",
    competitors: ["Epizyme", "Syros"],
    ipoDate: "Jul 2021",
    prices: [6, 6.3, 6.6, 6.9, 7.1, 7.4, 7.6, 7.8, 7.5, 7.2, 7, 6.8],
    website: "https://omegatx.com"
  },
  {
    name: "Arcutis Biotherapeutics",
    summary: "Develops topical immuno-dermatology drugs.",
    ticker: "ARQT",
    candidate: "Roflumilast Cream",
    indication: "Seborrheic Dermatitis",
    phase: "Approved 2024; expansion into pediatric use.",
    trialStatus: "Ongoing post-approval studies.",
    competitors: ["Dermavant", "Pfizer"],
    ipoDate: "Jan 2020",
    prices: [10, 10.5, 11, 11.5, 11.8, 12, 12.2, 12.5, 12.7, 12.3, 12, 11.8],
    website: "https://www.arcutis.com"
  },
  {
    name: "Entrada Therapeutics",
    summary: "Developing intracellular biologics using proprietary peptide delivery.",
    ticker: "TRDA",
    candidate: "ENTR-601-44",
    indication: "Duchenne Muscular Dystrophy (Exon 44)",
    phase: "Phase I",
    trialStatus: "First-in-human study initiated Q1 2025.",
    competitors: ["Sarepta", "Wave Life Sciences"],
    ipoDate: "Oct 2021",
    prices: [16, 16.5, 17, 17.2, 17.6, 18, 18.3, 18.5, 18.7, 18.3, 18, 17.8],
    website: "https://www.entradatx.com"
  },
  {
    name: "Vaxcyte",
    summary: "Next-gen conjugate vaccines for pneumonia and strep infections.",
    ticker: "PCVX",
    candidate: "VAX-24",
    indication: "Pneumococcal Disease",
    phase: "Phase III",
    trialStatus: "Pivotal trials enrolling globally in 2025.",
    competitors: ["Pfizer", "Merck"],
    ipoDate: "Jun 2020",
    prices: [45, 46, 47, 48, 49, 50, 52, 51, 50, 49, 48, 47],
    website: "https://vaxcyte.com"
  },
  {
    name: "Tenaya Therapeutics",
    summary: "Gene therapies targeting inherited heart disease.",
    ticker: "TNYA",
    candidate: "TN-201",
    indication: "Hypertrophic Cardiomyopathy",
    phase: "Phase I",
    trialStatus: "Patient dosing underway; initial data late 2025.",
    competitors: ["Rocket Pharma", "Cytokinetics"],
    ipoDate: "Jul 2021",
    prices: [12, 12.3, 12.5, 12.7, 13, 13.3, 13.5, 13.8, 14, 13.5, 13.2, 13],
    website: "https://www.tenayatherapeutics.com"
  },
  {
    name: "Karuna Therapeutics",
    summary: "Developing neuropsychiatric treatments including for schizophrenia.",
    ticker: "KRTX",
    candidate: "KarXT",
    indication: "Schizophrenia",
    phase: "NDA filed; FDA decision expected Q3 2025.",
    trialStatus: "Registration pending review.",
    competitors: ["Acadia", "Lundbeck"],
    ipoDate: "Nov 2019",
    prices: [200, 202, 205, 207, 210, 215, 218, 220, 222, 218, 216, 213],
    website: "https://karunatx.com"
  },
  {
    name: "Chinook Therapeutics",
    summary: "Precision therapies for kidney diseases.",
    ticker: "KDNY",
    candidate: "Atrasentan",
    indication: "IgA Nephropathy",
    phase: "Phase III",
    trialStatus: "Final data due Q4 2025.",
    competitors: ["Calliditas", "Novartis"],
    ipoDate: "Jun 2020",
    prices: [18, 18.3, 18.5, 18.7, 19, 19.5, 19.8, 20, 20.2, 19.9, 19.5, 19.2],
    website: "https://www.chinooktx.com"
  }

];


  const container = document.getElementById('stock-sections');

  pipeline.forEach((stock, idx) => {
    const col = document.createElement('div');
    col.className = 'col-12 col-md-6 col-lg-4 d-flex mb-4 px-3';

    col.innerHTML = `
      <div class="stock-card w-100" data-aos="fade-up" data-aos-delay="${(idx + 1) * 100}">
        <h5>${stock.name} (${stock.ticker})</h5>
        <p><strong>Summary:</strong> ${stock.summary}</p>
        <p><strong>Candidate:</strong> ${stock.candidate}<br>
           <strong>Indication:</strong> ${stock.indication}<br>
           <strong>Trial Phase:</strong> ${stock.phase}<br>
           <strong>Status:</strong> ${stock.trialStatus}</p>
        <p><strong>Competitors:</strong> ${stock.competitors.join(', ')}</p>
        <p><strong>IPO:</strong> ${stock.ipoDate}</p>
        <ul class="price-list">
          ${stock.prices.map((p, i) => `<li>${labels[i]}: $${p.toFixed(2)}</li>`).join("")}
        </ul>
        <canvas id="chart-${stock.ticker}" height="120"></canvas>
        <div class="card-footer">
          <a href="${stock.website}" target="_blank" class="btn btn-outline-primary btn-sm">Website</a>
          <a href="https://finance.yahoo.com/quote/${stock.ticker}" target="_blank" class="btn btn-primary btn-sm">Yahoo Finance</a>
        </div>
      </div>
    `;
    container.appendChild(col);
  });

  pipeline.forEach(stock => {
    const ctx = document.getElementById(`chart-${stock.ticker}`).getContext('2d');
    new Chart(ctx, {
      type: 'line',
      data: {
        labels: labels,
        datasets: [{
          label: `${stock.ticker} Stock`,
          data: stock.prices,
          borderColor: '#1a73e8',
          backgroundColor: 'rgba(26, 115, 232, 0.1)',
          tension: 0.3,
          fill: true
        }]
      },
      options: {
        responsive: true,
        plugins: { legend: { display: false } },
        scales: { x: { display: false }, y: { display: false } }
      }
    });
  });
</script>

</body>
</html>
